June 8, 2015
7:30 am | Registration |
8:00 am |
Welcome from the National Cancer Policy Forum |
Sharyl Nass, Institute of Medicine | |
Director, National Cancer Policy Forum | |
Overview of the Workshop |
|
Michael Kastan, Duke Cancer Institute | |
Planning Committee Chair | |
8:15 am |
Session 1: Overview and Value of Trials That Include |
Pets in Translational Cancer Research | |
Moderator: Michael Kastan, Duke Cancer Institute | |
Overview of current challenges and opportunities in oncology drug development |
|
Lee Helman, National Cancer Institute | |
Strengths and limitations of traditional preclinical models |
|
Beverly Teicher, National Cancer Institute |
Advantages and experiences with trials that include animal patients |
|
Chand Khanna, National Cancer Institute | |
Group Discussion |
|
10:10 am |
Break |
10:20 am |
Session 2: Canine Tumor Biology and Genomics Informing Cancer Drug Development |
Moderator: Deborah Knapp, Purdue University | |
The current state of canine tumor genetics and scientific limitations |
|
Heidi Parker, National Human Genome Research Institute | |
Use and availability of canine cancer tissue banks in translational research |
|
Matthew Breen, North Carolina State University | |
Genomic resources for canine cancer research |
|
Jessica Alföldi, Broad Institute of the Massachusetts Institute of Technology and Harvard University | |
Biology and informatics needs |
|
Jeff Trent, Translational Genomics Research Institute | |
Group Discussion |
|
12:15 pm |
Lunch Break |
1:00 pm |
Session 3: Effectively Integrating Biomarkers into Study Designs |
Moderator: Carl Barrett, AstraZeneca | |
Opportunities for preclinical evaluation of novel therapies |
|
Timothy Fan, University of Illinois at Urbana-Champaign |
Pharmacokinetic (PK) assessment |
|
Dan Gustafson, Colorado State University | |
Pharmacodynamics (PDs) and potential predictive biomarkers |
|
Doug Thamm, Colorado State University | |
Group Discussion |
|
2:30 pm |
Session 4: Effectively Integrating Imaging Technologies into Study Designs |
Moderator: Peter Choyke, National Cancer Institute | |
Role of trials that include pets in the development of new imaging modalities |
|
Peter Choyke, National Cancer Institute | |
Role of magnetic resonance imaging in studying tumor physiology: A clinical perspective |
|
Mark Dewhirst, Duke University | |
Group Discussion |
|
3:30 pm |
Break |
3:45 pm |
Session 5: Mechanisms for Comparative Oncology Trials |
Moderator: Lou DeGennaro, Leukemia & Lymphoma Society | |
Single-institution studies |
|
Cheryl London, Ohio State University | |
Multi-institution studies |
|
Amy LeBlanc, National Cancer Institute | |
Group Discussion |
|
4:45 pm |
Wrap Up Day 1 |
June 9, 2015
7:30 am |
Registration |
8:00 am |
Session 6: Addressing the Needs of Pet Animals and Their Owners |
Moderator: Michael Lairmore, University of California, Davis | |
Trial design and appropriate oversight |
|
David Vail, University of Wisconsin–Madison | |
Best practices for conduct of clinical trials for animal patients |
|
Rod Page, Colorado State University | |
Patricia Olson, Independent Advisor on Animal Health and Welfare | |
Group Discussion |
|
9:45 am |
Break |
10:00 am |
Session 7: The Status of Comparative Oncology in Drug Development |
Moderator: Perry Nisen, Sanford-Burnham Medical Discovery Institute | |
Panelists: |
|
Anne Keane, Achaogen | |
John Leighton, Food and Drug Administration | |
Wendy Levin, Fate Therapeutics | |
Daniel Tumas, Gilead Sciences, Inc. | |
Group Discussion |
|
11:30 am |
Workshop Wrap Up |
Deborah Knapp, Purdue University | |
Len Lichtenfeld, American Cancer Society | |
12:00 pm |
Adjourn |